Lyme Disease Vaccine Candidate Just Misses Its Mark in Late-Stage Trial
(MedPage Today) -- WASHINGTON -- An investigational Lyme disease vaccine covering six serotypes across four Borrelia species had a vaccine efficacy (VE) rate of over 70%, but it just missed a preset noninferiority threshold, a placebo-controlled...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.